WillItSurvive
No grouping · United States

Salspera Inc.

Clinical-stage biotech testing an engineered Salmonella-IL2 therapy for pancreatic cancer.

Protection under test
Assessed 29 July 2026 · Evidence as of 29 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 29 July 2026 · Checkable from 2026 · Every call on the record Checkpoint: IPO pricing and Nasdaq listing under ticker TKVA, still shown as Pending
The call

Salspera's future rests on Phase 3 data years away, funded by a still-unpriced IPO and run by a two-person team with no pharma partner yet on the table.

Salspera is a two-person company testing an engineered bacteria called Saltikva as a cancer treatment. The drug itself has legal protections that make it hard to copy, but the real problem is that the company only has about $900,000 in the bank and is trying to raise $85-91 million through an IPO to pay for a multi-year trial. Nobody else is making this exact drug, and there is no AI company trying to replace it, but Salspera could run out of money before it gets answers about whether Saltikva actually works. The one thing that could change everything is whether big investment firms like RA Capital or Baker Bros. actually buy shares in the IPO and stick around for the long haul, or whether the company stays so under-funded that it cannot last until the trial finishes.

Why
01
AI pressure: None apparent. No AI-native drug discovery rival is named as displacing Saltikva; the fight here is trial data and cash, not algorithms. Could AI do the core job? Unlikely.
02
Bigger players: Big pharma KRAS inhibitor and mRNA vaccine programs (e.g. Amgen, BioNTech-style approaches) in pancreatic cancer. Larger, better-funded programs are advancing competing pancreatic cancer treatments while Salspera still runs on two employees and pre-IPO cash. Could a giant copy it? Probably.
03
What protects it. Orphan-drug status and IP around its engineered Salmonella-IL2 platform, plus Phase 2 data beating historical FOLFIRINOX benchmarks.
What would change this call
Whether TKVA actually prices and begins trading on Nasdaq versus staying listed as Pending/$0.00. Shows whether Salspera can access public capital at all to fund Phase 3.
Presence or absence of a named institutional lead investor or pharma partner on the post-IPO cap table within 90 days. Indicates whether serious capital views the Salmonella-IL2 asset as credible.
Whether Salspera's headcount grows beyond 2 employees as trial operations are supposed to scale. Tests whether the company has real operational capacity to run a Phase 3 trial.
Key numbers
  • IPO targeting $85M at midpoint, up to $91M with over-allotment (2026-03-11)
  • Net loss of $9.45M to $10.73M for FY2025 (2025-12-31)
  • Phase 2: 70% overall response rate, 20.3-month median OS (2026-03-03)
Named risks
  • Thin capitalization with only ~$900K pre-IPO cash and no institutional backers as of Feb 2026. Severity: high
  • Phase 3 pivotal trial still in design, interim results not expected for 4+ years. Severity: high
  • IPO status unresolved, TKVA shown as Pending/$0.00 as of July 29, 2026. Severity: medium
  • Only 2 employees attempting to run a multi-year, multi-site Phase 3 oncology trial. Severity: high
  • Phase 2 efficacy data from open-label single-arm design compared to historical controls, not randomized. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Actym TherapeuticscontestingRival Salmonella Typhimurium platform, ACTM-838 in Phase 1a/b as of mid 2025
Precigenlosing toPrecigen has FDA-approved commercial immunotherapy PAPZIMEOS with revenue as of Jan 2026, Salspera has none
BioNTech, Moderna, Elicio pancreatic programsgaining on40+ sponsors pursuing KRAS inhibitors and mRNA vaccines in pancreatic cancer as of June 2026
Questions people ask
Is Salspera profitable in 2026?
No. Salspera reports zero product revenue and a net loss of approximately $9.45M to $10.73M for the twelve months ended December 31, 2025, per its S-1/A filing dated February 22, 2026. The company is pre-commercial with its only asset, Saltikva, still in trials.
Has Salspera's IPO actually priced yet?
As of July 29, 2026, live-quote sources still show ticker TKVA at '$0.00 / Pending,' indicating the IPO had not completed trading despite the S-1 filing on February 2, 2026 and terms disclosed February 23, 2026 targeting an $85M to $91M raise.
How many employees does Salspera have?
Salspera has exactly 2 named employees as of March 11, 2026: CEO Eddie Moradian, Ph.D., who previously ran contract research organization MD Biosciences, and CMO Daniel Saltzman, M.D., developer of the live biotherapeutics platform, per Fierce Biotech.
Who is Salspera's biggest competitor?
Actym Therapeutics, founded the same year as Salspera (2017), uses a comparable attenuated Salmonella Typhimurium platform (STACT) for solid tumors, with lead candidate ACTM-838 in Phase 1a/b as of mid 2025, per the company's own pipeline page.
Could AI replace what Salspera does?
No. Salspera's core value lies in wet-lab strain engineering and FDA clinical trials, a domain frontier AI does not replace. Its defensible assets are three patent families (US patents issued Feb 2023 and Sept 2024) and FDA Orphan Drug/Fast Track designations, not software-automatable processes.
What is Saltikva and what is it for?
Saltikva is Salspera's lead product: an orally dosed, genetically attenuated Salmonella Typhimurium strain engineered to express human IL-2 within the tumor microenvironment. It targets stage IV pancreatic ductal adenocarcinoma and osteosarcoma, per the February 22, 2026 IPO prospectus.
Timeline
  • 2026-07-29TKVA shows $0.00/Pending on live-quote sources, IPO not yet trading
  • 2026-06-09Third-party report cites 40+ sponsors competing in pancreatic cancer treatment
  • 2026-03-11Fierce Biotech reports IPO offer size up to $91M with over-allotment option
  • 2026-03-03Phase 2 results reported: 15mo PFS, 20.3mo OS, 70% ORR for Saltikva plus FOLFIRINOX
  • 2026-02-26Seeking Alpha flags Salspera as thinly capitalized with no institutional backing
  • 2026-02-23S-1/A discloses IPO terms: 5.67M shares at $14 to $16, targeting $85M midpoint
  • 2026-02-02Salspera files public S-1 for Nasdaq IPO under ticker TKVA
  • 2025-11FDA grants Orphan Drug Designation for osteosarcoma indication
  • 2025-09-12Salspera files confidentially with SEC ahead of public IPO filing
  • 2022-05FDA grants Orphan Drug and Fast Track Designation for pancreatic cancer
Revision history
29 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
Ford MotorWhirlpoolSolventum
More companies protection under test →
Sources